Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced participation and a fireside chat at Piper Sandler's 36th Annual Healthcare Conference:
加利福尼亞州門羅公園，2024年11月19日（全球新聞網）—— Oruka Therapeutics, Inc.（「Oruka」）（納斯達克：ORKA），是一家開發新型生物製品的生物技術公司，旨在爲包括斑塊狀銀屑病在內的慢性皮膚疾病的治療樹立新的標準，今天宣佈參加派傑投資第36屆年度醫療健康大會並進行爐邊聊天：
Date: Tuesday, December 3rd, 2024
Time: 3:00PM ET
日期：2024年12月3日，星期二
時間：東部時間下午3:00
About Oruka Therapeutics
全新的生物製品研發公司Oruka Therapeutics正致力於開發針對慢性皮膚病的全新生物製品，以實現全面治癒患有牛皮癬等慢性皮膚病患者的使命。Oruka正在推進由Paragon Therapeutics工程團隊設計的一系列專有的抗體，這些抗體是可能最好的類似產品，並針對牛皮癬和其他皮膚炎症疾病的核心機制。欲了解更多信息，請訪問www.orukatx.com。
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.
Oruka Therapeutics正在開發新穎的生物製品，旨在爲慢性皮膚病的治療樹立新標準。Oruka的使命是通過每年一到兩次的劑量給予患有銀屑病等慢性皮膚病的患者帶來最大可能的康復自由。Oruka正在推進Paragon Therapeutics工程化的專有抗體組合，這些抗體有望成爲最優秀的抗體，靶向銀屑病和其他皮膚病和炎症性疾病的核心機制。更多信息請訪問 and 關注Oruka的LinkedIn。
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
投資者聯繫：
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
